loading page

Targeting STAT3 Signaling Pathway by Curcumin and Its analogues for Breast Cancer: An Overview and Update on New Developments
  • +7
  • Mohammad Yassin Zamanian,
  • Maryam Golmohammadi,
  • Ahmed Muzahem Al-Ani,
  • Thaer L.Jabbar,
  • Ali Kamil Kareem,
  • Zeinab Hashem Aghaei,
  • Hossein Tahernia,
  • Ahmed Hjazi,
  • Saad Abdul-ridh Jissir,
  • Elham Hakimizadeh
Mohammad Yassin Zamanian
Hamadan University of Medical Sciences Medical School

Corresponding Author:[email protected]

Author Profile
Maryam Golmohammadi
Shahid Beheshti University of Medical Sciences School of Medicine
Author Profile
Ahmed Muzahem Al-Ani
Al-Nisour University College
Author Profile
Thaer L.Jabbar
Al- Ayen University
Author Profile
Ali Kamil Kareem
Al-Mustaqbal University College
Author Profile
Zeinab Hashem Aghaei
Shahid Beheshti University of Medical Sciences Preventative Gynecology Research Center
Author Profile
Hossein Tahernia
Rafsanjan University of Medical Sciences
Author Profile
Ahmed Hjazi
Prince Sattam bin Abdulaziz University College of Applied Medical Sciences
Author Profile
Saad Abdul-ridh Jissir
Al-Bayan University
Author Profile
Elham Hakimizadeh
Rafsanjan University of Medical Sciences
Author Profile


Breast cancer (BC) has emerged as the fifth most prevalent cause of cancer-related morbidity, prompting considerable interest from researchers due to its increased malignancy and resistance to drugs. Traditional chemotherapy methods have demonstrated limited effectiveness in treating all BC subtypes, underscoring the pressing demand for innovative therapeutic strategies or medications. Curcumin, a bioactive substance extracted from Curcuma longa, has been widely examined for its potential as an oncology drug. Research indicates that turmeric extract and its derivatives effectively inhibit STAT3, resulting in downstream effects like reducing cancer cell growth, triggering cell death, and preventing metastasis. The research on curcumin’s impact on the STAT3 pathway in BC demonstrated that curcumin effectively inhibits STAT3, leading to downstream effects such as the downregulation of Bcl-xL, Bcl-2, and Survivin, and the induction of apoptosis in H-Ras MCF10A cells. Additionally, it showed curcumin’s ability to hinder proliferation and anchorage-independent cell growth. The research also examined the effects of curcumin derivatives, like FLLL11, FLLL12, hydrazinocurcumin (HC), and GO-Y030, on STAT3 inhibition and their potential as therapeutic agents for BC. Observed results indicated the promise of curcumin and its derivatives in targeting the STAT3 signaling pathway for BC therapy.